Posted by Michael Wonder on 06 Dec 2022
Syndax announces US FDA breakthrough therapy designation granted for revumenib for the treatment of adult and paediatric patients with relapsed or refractory KMT2A rearranged acute leukaemia
5 December 2022 - Revumenib is the first and only investigational treatment for R/R KMT2Ar acute leukaemia to receive breakthrough therapy designation.
Syndax Pharmaceuticals today announced that the US FDA has granted breakthrough therapy designation for revumenib for the treatment of adult and paediatric patients with relapsed or refractory acute leukaemia harbouring a KMT2A rearrangement.
